International Journal of Drug Delivery Technology
Volume 14, Issue 3

Application of Box-Behnken Design for Formulation Optimization of Sorafenib loaded Nanoparticles Targeting to Liver Carcinoma: Ex-vivo Intestinal Permeation and Cytotoxicity Study

Gnyana Ranjan Parida1, Gurudutta Pattnaik1, Amulyaratna Behera2,Dibya Lochan Mohanty3, Suraj Sahoo4

1School of Pharmacy and Life Sciences, Centurion University of Technology and Management, Odisha, India.

2School of Pharmacy, Driems University, Cuttack, Odisha, India.

3Centre for Nanomedicine, School of Pharmacy, Department of Pharmaceutics, Anurag University, Hyderabad, India.

4Sri Jayadev College of Pharmaceutical Sciences, Bhubaneswar, Odisha, India.

 

Received: 12 th March, 2024; Revised: 03rd May, 2024; Accepted: 2nd August, 2024; Available Online: 25th September, 2024

 ABSTRACT

The anticancer drug sorafenib (SFB) was formulated as a polymeric nanoparticle using Box-Behnken design. The solvent evaporation method was utilized to develop the sorafenib polymeric nanoparticles. Formulations were then evaluated in terms of their morphological structure, entrapment efficiency (EE%), zeta potential, polydispersity index (PDI), and particle size. Ex-vivo intestinal permeation studies for pure drugs, as well as optimized formulation, were performed in rats. Furthermore, the anticancer activity was evaluated using the HepG2 cancer cell lines. Transmission electron microscopy (TEM) revealed that the improved formulation had a particle size of 175 nm, PDI of 0.134, zeta-potential of -23.8 mV, and the sorafenib-loaded PLGA NP were recognized as spherical particles. Over 90% of the drug was released in less than 24 hours, with an EE% of 85.1%. Sorafenib-loaded PLGA NP efficiently inhibited HepG2 cells.

Keywords: Sorafenib, Nanoparticles, Hep G2 cell lines, Anticancer activities.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.25

How to cite this article: Parida GR, Pattnaik G, Behera A, Mohanty DL, Sahoo S. Application of Box-Behnken Design for Formulation Optimization of Sorafenib loaded Nanoparticles Targeting to Liver Carcinoma: Ex-vivo Intestinal Permeation and Cytotoxicity Study. International Journal of Drug Delivery Technology. 2024;14(3):1426-1434.

REFERENCES

  1. Balogh J, Victor III D, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour Jr HP. Hepatocellular carcinoma: a Journal of hepatocellular carcinoma. 2016 Oct 5:41-53. doi: 10.2147/JHC.S61146
  2. Hao X, Fan R, Zeng HM, Hou JL. Hepatocellular carcinoma risk scores from modelling to real clinical practice in areas highly endemic for hepatitis B Journal of Clinical and Translational Hepatology. 2023 Dec 12;11(7):1508.
  3. Jafri W, Kamran Hepatocellular carcinoma in Asia: a challenging situation. Euroasian journal of hepato- gastroenterology. 2019 Jan;9(1):27.
  4. Mazzoccoli G, Miele L, Oben J, Grieco A, Vinciguerra M. Biology, epidemiology, clinical aspects of hepatocellular carcinoma and the role of sorafenib. Current drug targets. 2016 Jun 1;17(7):783-99.
  5. Chen F, Fang Y, Chen X, Deng R, Zhang Y, Shao J. Recent advances of sorafenib nano formulations for cancer therapy: Smart nanosystem and combination therapy. Asian journal of pharmaceutical sciences. 2021 May 1;16(3):318-36.
  6. Mans JC, Dong X. The Development of Lipid-Based Sorafenib Granules to Enhance the Oral Absorption of Sorafenib. 2023 Nov 28;15(12):2691. doi: 10.3390/ pharmaceutics15122691
  7. Kabil MF, Nasr M, El-Sherbiny IM. Conventional and hybrid nanoparticulate systems for the treatment of hepatocellular carcinoma: An updated review. European journal of pharmaceutics and biopharmaceutics. 2021 Oct 1;167:9-37.
  8. Wang L, Chen M, Ran X, Tang H, Cao Sorafenib-Based Drug Delivery Systems: Applications and Perspectives. Polymers. 2023 Jun 9;15(12):2638. doi: 10.3390/polym15122638Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L,
  9. Wen Y, Zhang ZJ. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics. 2021;11(11):5464. doi: 10.7150/thno.54822
  10. Sabit H, Abdel-Hakeem M, Shoala T, Abdel-Ghany S, Abdel- Latif MM, Almulhim J, Mansy M. Nanocarriers: a reliable tool for the delivery of anticancer drugs. Pharmaceutics. 2022 Jul 28;14(8):1566.
  11. Ye H, Zhou L, Jin H, Chen Y, Cheng D, Jiang Y. Sorafenib- loaded long-circulating nanoliposomes for liver cancer therapy. BioMed Research 2020 May 6;2020. doi: 10.1155/2020/1351046
  12. Wang H, Wang H, Yang W, Yu M, Sun S, Xie B. Improved oral bioavailability and liver targeting of sorafenib solid lipid nanoparticles in AAPS PharmSciTech. 2018 Feb;19:761-8. doi: 10.1208/s12249-017-0901-3
  13. Wang Z, Duan X, Lv Y, Zhao Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers. Life sciences. 2019 Dec 15;239:117013.
  14. Su Y, Wang K, Li Y, Song W, Xin Y, Zhao W, Tian J, Ren L, Lu L. Sorafenib-loaded polymeric micelles as passive targeting therapeutic agents for hepatocellular carcinoma therapy. Nanomedicine. 2018 May 1;13(9):1009-23.
  15. Cai H, Yang Y, Peng F, Liu Y, Fu X, Ji B. Gold nanoparticles- loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells. International journal of medical sciences. 2019;16(12):1541. doi: 10.7150/ijms.37427
  16. Walbi IA, Ahmad MZ, Ahmad J, Algahtani MS, Alali AS, Alsudir SA, Aodah AH, Albarqi HA. Development of a curcumin-loaded lecithin/chitosan nanoparticle utilizing a box- behnken design of experiment: formulation design and influence of process parameters. Polymers. 2022 Sep 8;14(18):3758.
  17. Mohanty D, Gilani SJ, Zafar A, Imam SS, Kumar LA, Ahmed MM, Jahangir MA, Bakshi V, Ahmad W, Eltayib EM. Formulation and optimization of alogliptin-loaded polymeric nanoparticles: In vitro to in vivo assessment. Molecules. 2022 Jul 13;27(14):4470. doi: 10.3390/molecules27144470
  18. Anit J. George Fels Saju1, Bharat Mishra, Development of size optimized bromelain loaded nanocarriers by box behnken design, International journal Drug Delivery Technology 2023;13(1):10-doi: 10.25258/ijddt.13.1.02
  19. Mohanty D, Alsaidan OA, Zafar A, Dodle T, Gupta JK, Yasir M, Mohanty A, Khalid Development of atomoxetine-loaded NLC in situ gel for nose-to-brain delivery: optimization, in vitro, and preclinical evaluation. Pharmaceutics. 2023 Jul 20;15(7):1985. doi: 10.3390/pharmaceutics15071985
  20. Chekkilla Bhargavi, Pathuri Raghuveer, Development of piribedil solid lipid nanoparticles incorporated in nasal in-situ gel by DoE, International Journal of Pharmaceutical Quality Assurance. 2024;15(1):199-209. doi: 10.25258/ijpqa.15.1.31
  21. Atul Pund , Atishkumar Mundada, Formulation development and evaluation of brivaracetam extended release tablets by QbD approach, International Journal of Pharmaceutical Quality Assurance. 2024;15(1):372-381. doi: 10.25258/ijpqa.15.1.59
  22. Chougule PN, Koumaravelou K, Chougule NB, Fabrication, optimization and evaluation of escin enriched emulgel system for treatment of varicose veins, International Journal of Drug Delivery Technology. 2023;13(3):833-841. doi: 10.25258/ 13.3.10
  23. Barzegar-Jalali An Alternative Approach for ImprovedEntrapment Efficiency of Hydrophilic Drug Substance in PLGA Nanoparticles by Interfacial Polymer Deposition Following Solvent Displacement. Jundishapur Journal of Natural Pharmaceutical Products.;13(4).
  24. Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug International journal of pharmaceutics. 2007 May 24;336(2):367- 75.
  25. Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M. Drug release study of the chitosan-based Heliyon. 2022 Jan 1;8(1). doi: 10.1016/j.heliyon.2021.e08674
  26. Hua Advances in oral drug delivery for regional targeting in the gastrointestinal tract-inf luence of physiological, pathophysiological and pharmaceutical factors. Frontiers in pharmacology. 2020 Apr 28;11:524.
  27. Singh C, Yashwant Formulation and the Study of FinishedProducts used for Anginal Disease.Faris TM, Harisa GI, Alanazi FK, Samy AM, Nasr Developed simvastatin chitosan nanoparticles co-crosslinked with tripolyphosphate and chondroitin sulfate for ASGPR-mediated targeted HCC delivery with enhanced oral bioavailability. Saudi Pharmaceutical Journal. 2020 Dec 1;28(12):1851-67.